Sage Journals: Discover world-class research

Abstract

Atherosclerosis is a chronic inflammatory disease affecting the vascular system, characterised by the accumulation of modified lipoproteins, immune cell aggregation and the development of fibrous tissue within blood vessel walls. As atherosclerosis impacts blood vessels, its adverse effects may manifest across various tissues and organs. In this review, we examine the association of atherosclerosis with Alzheimer’s disease, stroke, pancreatic and thyroid dysfunction, kidney stones and chronic kidney diseases. In several cases, the reciprocal causative effect of these diseases on the progression of atherosclerosis is also discussed. Particular attention is given to common risk factors, biomarkers and identified molecular mechanisms linking the pathophysiology of atherosclerosis to the dysfunction of multiple tissues and organs. Understanding the role of atherosclerosis and its associated microenvironmental conditions in the pathology of multi-organ disorders may unveil novel therapeutic avenues for the prevention and treatment of cardiovascular and associated diseases.

Keywords

Atherosclerosis Alzheimer’s disease stroke kidney stones chronic kidney disease thyroid dysfunction

Introduction

Atherosclerosis is a chronic inflammatory disease and the primary driver of cardiovascular diseases (CVD), ultimately leading to myocardial infarction and stroke, and significantly contributing to mortality in Western nations.¹ The pathogenesis of atherosclerosis is conventionally divided into distinct ‘stages’ (e.g. initiation, progression and advanced stages with complications). Hypertension, hyperglycaemia, dyslipidaemia, diabetes mellitus, physical inactivity, obesity, poor nutrition, stress, environmental factors and genetic predisposition are recognised as major risk factors associated with atherosclerosis.² Moreover, atherosclerosis often coexists with a related condition known as arteriosclerosis. While atherosclerosis refers to the deposition of fibro-fatty lesions in arterial walls, arteriosclerosis is characterised by stiffening of the arterial media due to connective tissue degeneration, particularly of its main component, elastin. Unlike atherosclerosis, arteriosclerosis is considered a consequence of systolic hypertension resulting from aortic stiffening and other adverse haemodynamic effects.³

The initiation of atherosclerosis is characterised by the excessive accumulation of immune-reactive, multiple modified forms of low-density lipoprotein (LDL) particles (modified by glycation, oxidation, desialylation, dicarbonylation and other processes). These modifications induce inflammation, promote foam cell formation and stimulate both humoral and adaptive immunity.^4
–6 Thus, inflammation, lipid accumulation and oxidative damage are key processes involved in the initiation of atherosclerosis. As the disease progresses, the formation of a necrotic plaque core and the onset of mineralisation occurs. While extensive calcification can stabilise plaques, spotty calcification is known to reduce plaque stability, increasing the risk of rupture.^7,8 In the advanced stage, the growing atherosclerotic plaque disrupts normal blood flow and limits oxygen supply to tissues and organs (ischaemia).⁹ Advanced plaques are also prone to rupture, triggering acute thrombosis in blood vessels and causing myocardial infarction or stroke.¹⁰

As the vascular system is integral to all tissues and organs, atherosclerosis impacts the functionality of the entire body, extending beyond the typical anatomical sites (e.g. thoracic aorta, aortic valve or coronary artery) where atherosclerotic plaques are usually studied. The association of atherosclerosis with pathologies in numerous tissues and organs is well-documented and has been discussed extensively in recent reviews: heart,^11,12 liver,^13
–15 immune system,^16
–19 bone marrow,^20,21 lymph nodes and lymphoid organs,^22
–24 adipose tissue,^25,26 vascular smooth muscle cells,^27
–29 skin,^30
–32 gastrointestinal tract^33,34 and pancreas (in the context of diabetes).^35,36 Therefore, these topics will be excluded from this article. In this review, we focus on the association of atherosclerotic cardiovascular disease (ASCVD) with selected major organ systems and specific diseases: the brain (ischaemic stroke (IS) and Alzheimer’s disease (AD)), pancreas (beyond diabetes), kidneys (cholesterol crystal embolism (CCE), chronic kidney disease (CKD) and kidney stone (KS) disease) and thyroid dysfunction (hypo- and hyper-thyroidism). Our goal is to provide an updated conceptualisation of how atherosclerosis is implicated in and associated with these multi-organ pathologies, expanding our understanding of the underlying molecular mechanisms and offering new insights for the development of therapeutic opportunities.

Association between ASCVD and IS

IS, a cerebrovascular accident, is the second leading cause of morbidity and mortality worldwide, with over 13.7 million cases identified annually.³⁷ Atherosclerosis plays a crucial role in the pathogenesis of IS, characterised by vascular dysfunction and either significant stenosis or occlusion of a major brain artery (carotid or vertebral arteries) or a branch of a cortical artery (anterior, middle or posterior cerebral arteries), resulting in hypoxia-induced neuronal injury.³⁸ Other aetiological subtypes of IS include cardioembolism, small vessel occlusion, stroke of other aetiology (e.g. dissections or vasculitis) and stroke of undetermined aetiology.³⁹

Atherosclerosis and stroke share several risk factors, such as hypertension, type 2 diabetes (T2D) and metabolic syndrome, further highlighting the close association between these pathologies (Figure 1).⁴⁰ For instance, a recent study involving 23,973 Chinese participants with no history of CVD demonstrated that systolic blood pressure (BP) had a stronger association with IS than plaque burden. While plaque burden was not linked to probable cardioembolic stroke, it showed a stronger association with probable large artery stroke compared to lacunar stroke.⁴¹

Figure 1.

Potential pathophysiological mechanisms connecting atherosclerosis and stroke thought the common risk factors (diabetes, metabolic syndrome and hypertension). Oxidative stress and chronic low-grade inflammation are the main processes leading to endothelial dysfunction and arterial stiffness, and, eventually, resulted in atherosclerosis. Subsequently, atherosclerosis progression may lead to thrombosis, formation of unstable plaques and stenosis of blood vessels, which greatly increase the risk of stroke and other cardiovascular events. Post-stroke dementia is a common condition of stroke survivors, seen at a high rate shortly after stroke.

Moreover, many markers associated with atherosclerosis – such as biochemical parameters, inflammatory molecules, genetic factors and RNAs (micro-, circular-, long non-coding- and transfer RNA-derived small RNAs) – serve as prognostic indicators of mortality in stroke patients.⁴² For example, C-reactive protein (CRP), expressed in vascular smooth muscle cells and implicated in plaque destabilisation, has been recognised as an independent predictor of mortality in stroke patients, as well as for the risk of recurrent stroke.⁴³ Additionally, the recently identified Embryonic Lethal Abnormal Vision Drosophila-like protein 1 (ELAVL1) is associated with the development of CVD and cerebral ischaemia/reperfusion injury.⁴⁴ Serum ELAVL1 levels are higher in IS patients compared to carotid atherosclerosis patients and correlate positively with total cholesterol (TC), LDL-C, CRP and pro-inflammatory cytokines (tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6)), while negatively correlating with high-density lipoprotein-cholesterol (HDL-C). These findings suggest that serum ELAVL1 could serve as a biomarker for diagnosing IS.⁴⁵

Migraine, a complex neurological disorder characterised by episodic headaches, is a well-established risk factor for myocardial infarction, total haemorrhagic and IS.^46
–48 However, migraine is not associated with increased atherosclerosis in large vessels in acute ischaemic stroke (AIS) patients. On the contrary, studies suggest a lower prevalence of atherosclerotic changes in stroke patients with migraine. This indicates that the increased risk of IS in migraine patients may be based on pathological mechanisms other than atherosclerosis, warranting further investigation.⁴⁹

Modern imaging techniques, such as computed tomography (CT), are widely used to diagnose both atherosclerosis and stroke in clinical settings by evaluating plaque properties and calcification characteristics.^50,51 For example, the high prevalence of napkin-ring sign plaques observed in cervicocerebral CT angiography has been proposed as a significant risk factor for AIS. This biomarker may be particularly valuable for routine and emergency screening of asymptomatic atherosclerotic patients to identify their risk of AIS and apply timely anti-atherosclerotic therapies for prevention.⁵²

Vascular calcification, characterised by calcium–phosphate complex deposition in vessels, affects plaque stability (intimal calcification) and causes arterial stiffening (medial calcification). Among others, carotid artery calcification, intracranial artery calcification and coronary artery calcification are the most studied quantitative parameters for predicting the risk of atherosclerosis and stroke.^53,54 For instance, in AIS patients undergoing intravenous recombinant tissue plasminogen activator (thrombolysis) treatment, the total carotid siphon calcification score (8-point scale) was associated with mortality within the first 3 months.⁵⁵ Additionally, calcification volumes in major vessels (e.g. intracranial internal carotid artery, cervical carotid artery and aortic arch) were higher in AIS patients aged < 65 years with large artery atherosclerosis compared to other stroke aetiologies.⁵⁶ The specific “spotty” calcification pattern (small, scattered calcium deposits) has been linked to high-risk lesions.⁵⁷ Notably, recent research indicates that the prevalence of spotty calcification at the carotid bifurcation and siphon is associated with an increased risk of non-lacunar IS compared to control patients with subclinical atherosclerosis.⁵⁸ Interestingly, a study of 207 AIS patients revealed that high serum aldosterone levels independently predicted advanced intracranial arterial calcification and atherosclerosis.⁵⁹ These findings suggest that aldosterone, a key mineralocorticoid steroid hormone involved in atherosclerotic lesion progression,⁶⁰ may serve as a biomarker for atherosclerosis, arterial calcification and stroke risk.⁵⁹

Stroke survivors often experience post-stroke cognitive impairment (PSCI), ranging from mild cognitive decline to severe post-stroke dementia.⁶¹ Among AIS patients, both low and high systolic BP were associated with an increased risk of PSCI at 3 months. Additionally, large artery atherosclerosis and total anterior circulation infarct were linked to higher PSCI risk. These findings suggest that maintaining optimal BP levels may help reduce PSCI occurrence.⁶² In asymptomatic patients with significant carotid stenosis, the instability of atherosclerotic plaques at the carotid bifurcation was associated with subclinical microemboli and white matter hyperintensities, correlating with vascular cognitive decline.⁶³ Furthermore, a study involving 128 stroke patients found that progression and multiple calcifications of carotid artery plaques were associated with accelerated PSCI, whereas the absence or single calcifications were not.⁶⁴

Atherosclerosis significantly increases the risk of IS through mechanisms involving plaque formation, rupture and embolism. The presence of napkin-ring sign plaques, a ‘spotty’ pattern of plaque calcification, and elevated biomarkers such as aldosterone, CRP and ELAVL1 protein strongly correlate with stroke risk. These findings emphasise the need for early identification and management of atherosclerosis, especially in individuals at high risk for stroke. Stroke biomarkers and plaque characteristics could serve as key indicators for better prevention and treatment strategies.

Association between ASCVD and AD

AD is a progressive neurodegenerative condition characterised by the deposition of amyloid β (Aβ) and hyperphosphorylated tau protein aggregates in the brain, leading to significant cognitive decline.⁶⁵ Both AD and atherosclerosis have been identified as chronic low-grade inflammatory diseases that share common risk factors, such as ageing, hyperlipidaemia, vascular dysfunction and hypertension. These shared characteristics suggest a bidirectional relationship wherein each condition may promote the other’s progression (Figure 2).⁶⁶

Figure 2.

Interplay between cardiovascular risk factors and increased risk of Alzheimer’s disease. Hypertension can increase β-amyloid (Aβ) deposition and aggravate Aβ-induced cerebrovascular dysfunction. Also, hypertension could impair Aβ vascular clearance and increase its cleavage from the amyloid precursor protein (APP). Finally, hypertension can cause white matter injury, microbleeds, microinfarcts and facilitate development of cerebral atherosclerosis, which manifests by ischaemic stroke, chronic hemispheric hypoperfusion or cerebral hypoxia, thus triggering AD development. Diabetes and metabolic syndrome associated with AD through several underlying mechanisms, such as hyperglycaemia-induced toxicity, advanced glycation end product-induced adverse effects, insulin resistance, insulin receptor impairment, inflammation and cerebrovascular damage. Also, dyslipidaemia increased Aβ peptide deposition, promotes Tau hyperphosphorylation, compromised the integrity of the blood–brain barrier and promote neuroinflammation compatible with AD. The role of ASCVD in AD progression is depicted in solid lines; the role of AD in the progression of ASCVD is depicted in dashed lines.

The role of AD in atherosclerosis progression

The amyloid precursor protein (APP) and Aβ are produced in various tissues and organs outside the central nervous system, including the heart, endothelium, intestine, skin, muscle and adipose tissue.^67,68 Despite APP’s documented expression in endothelial cells and cardiomyocytes, its physiological and pathological roles in the cardiovascular system remain poorly understood.⁶⁹ Cohort-based analyses have demonstrated associations between elevated amyloid-beta 1-40 (Aβ40) levels and increased arterial stiffness, subclinical atherosclerosis and coronary heart disease (CHD), suggesting that Aβ may contribute to pathologies beyond AD.⁷⁰ Furthermore, APP overexpression has been shown to exacerbate endothelial dysfunction and atherosclerosis in ApoE^−/− mice, while APP deletion reduced atherogenesis in the same model.^71,72

Aβ-mediated oxidative damage, lipid oxidation and modification have been proposed as key mechanisms in the initiation of atherosclerosis.⁷³ For instance, the increased expression of chitinase-3-like protein 1 (Chi3l1) has been observed in the aortas of atherosclerotic patients⁷⁴ and in the brains of human APP-expressing mice.⁷⁵ High serum Chi3l1 levels have been linked to endothelial dysfunction and thromboembolic stroke.^76,77 Knockdown of Chi3l1 in ApoE^−/− mice suppressed the progression of atherosclerotic plaques.⁷⁴ It has also been shown that APP reduces the expression of miR-342-3p in arterial endothelium, thereby increasing Chi3l1 levels and promoting atherosclerosis.⁷⁸ These findings suggest that Chi3l1 is a critical pro-atherogenic factor, while miR-342-3p functions as an anti-atherogenic miRNA regulated by APP. This pathway holds potential as a novel diagnostic and therapeutic target for atherosclerosis.

Another mechanism implicates APP in platelet adhesion and thrombus formation. Platelets from APP knockout mice fail to adhere to immobilised Aβ peptides Aβ_1–40, Aβ_1–42 and Aβ_25–35. In contrast, blood from wild-type mice enhances adhesion to Aβ peptides co-coated with collagen. Aβ also promotes platelet aggregation and degranulation, further contributing to plaque progression and vascular complications.^79
–81

The role of atherosclerosis in AD progression

Atherosclerosis has also been identified as a predictive factor for accelerated cognitive decline in AD patients. Clinical and neuropsychological evaluations have revealed that increased carotid intimal medial thickness (IMT) correlates with faster deterioration in memory, executive function and semantic fluency in AD patients.⁸² Hypertension serves as a convergence point linking atherosclerosis and AD, acting as a well-recognised risk factor for both conditions.^83,84

Experimental models have further elucidated this connection. In TgSwDI mice (elevated Aβ levels only in the brain) and Tg2576 mice (elevated Aβ levels in both blood and brain), acute angiotensin II (ANGII) treatment aggravated cerebrovascular dysfunction exclusively in TgSwDI mice. ANGII was shown to enhance β-secretase activity, increasing the production of toxic Aβ_1–42 while reducing Aβ_1–40 levels. This pathway highlights the role of hypertension in APP processing and amyloidogenesis, thereby linking vascular dysfunction and AD progression.⁸⁵ Clinical studies have supported these findings, showing that hypertension promotes intracranial atherosclerosis, leading to cerebral hypoperfusion, arterial wall stiffening and the progression of AD pathology.⁸⁶

High-fat diet-fed Tg mice have demonstrated additional contributions of atherosclerosis to AD pathology, including hypercoagulation, thrombocytosis, chronic platelet activation and memory impairment. Procoagulant platelets facilitate the conversion of soluble Aβ40 into fibrillar aggregates, which obstruct cerebral blood vessels. These changes are accompanied by increased cerebral vascular permeability, heightened neuroinflammation, neuron loss and tau hyperphosphorylation.⁸⁷

The CCAAT/enhancer-binding protein beta (C/EBPβ)/asparagine endopeptidase (AEP) pathway has been identified as another shared mechanism between atherosclerosis and AD.^88,89 C/EBPβ is a transcription factor regulating inflammation and oxidative stress.^90,91 while AEP cleaves APP and tau, accelerating Aβ production and tau aggregation in AD and promoting foam cell formation and vascular remodelling in atherosclerosis.^92,93 Knockout studies in Tg and ApoE^−/− mice have shown that deletion of C/EBPβ or AEP reduces foam cell formation, arterial macrophage accumulation, cerebral blood flow impairment and cognitive deficits, thereby ameliorating both atherosclerosis and AD pathologies.^94
–98

Recent research on Tg and ApoE^−/− mice has further explained the C/EBPβ/AEP-mediated association between AS and AD. Therefore, macrophage-specific deletion of C/EBPβ or AEP decreased cholesterol load and reduced foam cell formation and lesions area in aorta of HFD-fed ApoE^−/− mice. Knock out of C/EBPβ or AEP from HFD-fed Tg/ApoE^−/− mice reduced the lesion area and arterial macrophage accumulation, increased cerebral blood flow and blood vessel length and restored cognitive deficits, thus ameliorating AD pathologies. Knock out of ApoE from hippocampus of Tg mice increased serum LDL and lesion areas in the aorta, reduced cerebral blood flow and vessel length and increased cognitive deficits, thus aggravating AD pathologies. These results showed that C/EBPβ/AEP signalling connected AS to AD through ApoE-mediated cerebral vasculature dysfunctions, where AS-induced brain hypoperfusion contributed to the AD progression.⁹⁹

The crucial role of ApoE in both AS and AD progression was shown also on humans, where neuropsychological evaluation of AD patients demonstrated that ApoE ε4 allele was associated with more severe forms of atherosclerosis and higher rate of cognitive decline in AD.¹⁰⁰ AD patients carrying the ApoE ε4 allele and affected by non-valvular atrial fibrillation exhibit the highest IMT, vascular damage and cognitive deficits.¹⁰¹

These findings suggest that atherosclerosis actively contributes to AD pathology through vascular dysfunction, cerebral hypoperfusion, blood coagulation and platelet-mediated Aβ aggregation, ultimately resulting in cognitive decline. Early detection and timely management of vascular risk factors could prevent or delay the progression of AD, highlighting the importance of integrated therapeutic approaches.

Atherosclerosis and AD are closely interconnected, with vascular dysfunction and inflammation playing central roles in both conditions. The C/EBPβ/AEP signalling pathway and the ε4 allele of ApoE contribute to the progression of both atherosclerosis and AD, with atherosclerosis worsening cognitive decline in AD patients. These findings suggest that targeting atherosclerotic mechanisms may offer therapeutic benefits for AD patients. A dual approach that addresses both cardiovascular and neurodegenerative factors could help slow the progression of both diseases.

Pancreas and ASCVD

The contribution of pancreatic dysfunction and associated metabolic deficiencies, such as insulin resistance and obesity, to the progression of atherosclerosis has been extensively investigated (Figure 3).^102
–105 This section explores the association between pancreatic pathologies – particularly pancreatic fat deposition – and atherosclerosis, alongside co-occurring conditions such as T2D and non-alcoholic fatty liver disease (NAFLD).

Figure 3.

The complex relationship between diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty pancreatic disease (NAFPD), and atherosclerosis. In the conditions of obesity and diabetes, the increased secretion of free fatty acids (FFA) from adipose tissue to the circulation lead to increased delivery of FFA to the pancreas and the liver. In the liver, the surplus of FFA facilitated the development of NAFLD and increased the production of very-low-density lipoproteins, which promoted the development of NAFPD. Also, metabolic syndrome, obesity and diabetes are associated with systemic low-grade inflammation and increased oxidative stress, which, altogether with β-cell lipotoxicity caused by a fat accumulation in the pancreas, leading to the vicious cycle that further aggravates metabolic diseases and NAFPD. Several shared risk factors connected discussed disease with higher risk for the development of atherosclerosis and other cardiovascular diseases.

Fat accumulation in the pancreas has long been recognised and is frequently associated with obesity and NAFLD.^106,107 Given the high prevalence of fatty pancreas in the general population, it is now regarded as a common disorder. In one study, 25.9% of subjects undergoing endoscopic ultrasonography were diagnosed with fatty pancreas, which was associated with elevated levels of hyperlipidaemia, aortic IMT, fatty liver frequency, ischaemic heart disease and uric acid levels.¹⁰⁸ Non-alcoholic fatty pancreas disease (NAFPD) has been linked to increased body mass index (BMI), β-cell dysfunction, pancreatic inflammation and fibrosis, all of which can progress to diabetes mellitus, metabolic syndrome or pancreatic cancer.^109,110 In patients with NAFLD, high-resolution ultrasonography revealed that 97% exhibited fat deposition in the pancreas. Furthermore, fatty pancreas presence was correlated with increased carotid IMT and carotid-femoral pulse wave velocity, with the grade of fatty pancreas showing a positive correlation specifically with carotid-femoral pulse wave velocity.¹¹¹ Another study demonstrated that individuals with NAFPD exhibited higher levels of epicardial adipose tissue and aortic IMT compared to healthy controls. Additionally, NAFPD, age and BMI were independently associated with increased aortic IMT.¹¹² A large-scale systemic evaluation further found carotid calcification to be more frequent in NAFPD patients, suggesting a potential link between NAFPD and systemic calcified atherosclerosis.¹¹³

Similarly, studies on T2D patients using CT have demonstrated that pancreatic fat deposition correlates with age, visceral fat area and vascular stiffness. Interestingly, the relationship between pancreatic fat and the prevalence of carotid artery plaque or vascular stiffness was only significant in non-obese patients, while in obese patients, no such association was observed.¹¹⁴ Another study on T2D patients reported a positive correlation between high pancreatic fat levels and carotid plaque formation, regardless of obesity status.¹¹⁵ Additionally, T2D patients were found to have more extensive splenic artery calcifications and a less-dense pancreatic arterial tree compared to non-diabetic controls.¹¹⁶

Atherosclerosis contributes to pancreas dysfunction by reducing blood flow, leading to islet hypoxia and β-cell dysfunction, which can result in NAFPD and potentially NAFLD and diabetes. The vascular impact of atherosclerosis on the pancreas further complicates the management of metabolic disorders. These findings suggest that improving vascular health in patients with metabolic diseases, such as diabetes, may help prevent further pancreatic dysfunction. Monitoring blood flow and vascular health could be crucial for early intervention in patients at risk for NAFPD.

Chronic kidney disease

CKD is characterised by the progressive decline of renal function, indicated by a reduction in the glomerular filtration rate over at least 3 months, accompanied by manifestations such as albuminuria and abnormal kidney morphology. CKD is recognised as a prevalent systemic condition, affecting approximately 10% of the global population.¹¹⁷ The disease is stratified into five stages, with stage 3b marking the irreversible point in disease progression. Patients in stage 5 develop end-stage renal disease (ESRD), characterised by severely diminished kidney function, often necessitating dialysis or kidney transplantation.^118,119 Diabetes and hypertension are the primary causes of CKD,^120,121 while CCE is frequently overlooked as a cause of CKD in patients with advanced atherosclerosis.¹²²

Importantly, CKD patients have an elevated risk of developing CVD, making cardiovascular complications, rather than kidney failure itself, the leading cause of mortality in CKD – primarily due to stroke or myocardial infarction.^123,124 In addition to traditional risk factors shared by CKD and CVD (such as diabetes mellitus, dyslipidaemia, hypertension, hyperuricaemia, obesity, advanced age, family history, tobacco use and male gender), non-traditional risk factors, including disruptions in calcium-phosphate metabolism, mineral and bone disorders, malnutrition, oxidative stress and uraemic toxins, play a crucial role in CKD-related atherosclerosis development.^125
–127 The roles of a disintegrin and metalloproteases (ADAM) 10 and 17 in both CKD and atherosclerosis have been excellently reviewed elsewhere,¹²⁸ therefore, will be omitted here.

The role of atherosclerosis in CKD

The rupture of atherosclerotic plaques exposes their core – comprising cholesterol, fatty substances and cellular debris – to the circulation. In the bloodstream, cholesterol crystals (CCs) can become lodged in arterioles, leading to CCE, which narrows or obliterates the arteriole lumen, causing ischaemia and infarction in various tissues and organs, including the brain, muscles, bones, kidneys, nerves, skin, eyes, gastrointestinal tract, visceral organs and extremities. Due to the kidneys’ anatomical proximity to the abdominal aorta and the extent of renal blood flow, cholesterol atheroembolism frequently targets the kidneys, potentially resulting in acute kidney failure.^129,130 CCE is now a recognised cause of renal failure in older adults with atherosclerosis. Risk factors for CCE are similar to those for atherosclerosis, including hypercholesterolaemia, hypertension, peripheral vascular disease, diabetes, abdominal aortic aneurysm, ischaemic cardiovascular disease, cerebrovascular disease, hypercoagulability, smoking, male gender, Caucasian ethnicity and other factors.¹³¹

The precise mechanisms underlying CCE remain incompletely understood. CCE is predominantly iatrogenic, often linked to invasive procedures involving the aorta or major arteries, such as coronary angioplasty, angiography or left heart catheterisation.^132,133 However, local tissue necrosis, inflammatory responses, activation of the renin–angiotensin–aldosterone system and complement activation triggered by CC are considered critical to CCE development.^134
–136

CCE is challenging to diagnose and often heralds severe and unstable atherosclerotic disease, frequently associated with acute cardiovascular events and poor outcomes.

The role of CKD in atherosclerosis development

Comparisons of atherosclerotic parameters between ESRD patients and healthy controls have revealed greater levels of inflammation, vascular dysfunction, malnutrition and calcification in ESRD patients undergoing haemodialysis.^137
–139 Elevated levels of von Willebrand factor, a marker of endothelial impairment, have also been observed in CKD and ESRD patients.¹⁴⁰ These findings suggest that CKD-related pathological changes exacerbate vascular conditions, thereby accelerating atherosclerosis development.

The impaired efficacy of glomerular filtration in CKD leads to metabolite accumulation, raising the hypothesis that certain toxic substances impair anti-oxidant systems and increase oxidative stress and reactive oxygen species (ROS) production. Among these, several tryptophan-derived metabolites have been identified as ROS-generating uraemic toxins, including indoxyl sulphate and kynurenines (3-hydroxykynurenine, kynurenic acid and hydroxyanthranilic acid),¹⁴¹ which we discuss further (Figure 4).

Figure 4.

The role of CKD-associated pathological changes in the increased risk of atherosclerosis and other cardiovascular diseases. CKD-specific primary pathologic changes (such as uraemic toxins, albuminuria, anaemia and others) (depicted in fuchsia box) lead to secondary damage to cardiovascular system (such as endothelial dysfunction, oxidative stress and others) (depicted in magenta box) which lead to the remodelling of the myocardium and blood vessels (depicted in red box). These processes further contribute to the development and progression of atherosclerosis and other cardiovascular diseases.

Indoxyl sulphate has been shown to contribute to vascular injury by increasing endothelial susceptibility to oxidative stress. Experiments on human umbilical vein endothelial cells (HUVEC) demonstrated that indoxyl sulphate reduces cell viability, increases ROS production and causes mitochondrial dysfunction – manifested as reduced mitochondrial membrane potential, DNA copy number and mass.¹⁴² Additionally, indoxyl sulphate up-regulates miR-34a, which targets neurogenic locus notch homolog protein 1 (Notch1), affecting its downstream pathways and impairing endothelial cell proliferation and migration while promoting apoptosis.¹⁴³

Further studies have shown that NADPH oxidase-derived ROS plays a crucial role in activating the MAPK/NFκB/Activator protein 1 (AP-1) pathway in indoxyl sulphate-treated HUVEC. This pathway activation enhances the production of E-selectin, a key adhesion molecule responsible for recruiting leukocytes to inflammatory sites.¹⁴⁴ In human aortic endothelial cells, indoxyl sulphate treatment increased NADPH oxidase activity while reducing endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production, thereby promoting endothelial dysfunction.¹⁴⁵ Similar results were observed in another study, where indoxyl sulphate-treated HUVEC exhibited increased ROS production alongside decreased eNOS and VE-cadherin expression.¹⁴⁶ In vivo, CKD mice acutely and chronically exposed to indoxyl sulphate showed elevated expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), indicating endothelial activation and atherosclerosis progression.¹⁴⁷

Toxic metabolites from the tryptophan–kynurenine pathway have also been implicated in endothelial dysfunction, inflammation and atherosclerosis.^148
–150 For example, indoleamine 2,3-dioxygenase 1 (IDO1), the enzyme responsible for the first and rate-limiting step in tryptophan metabolism along this pathway, is up-regulated in coronary atherosclerotic plaques from patients with unstable angina pectoris compared to stable cases. IFNγ and TNFα further induce IDO1 expression, increasing the kynurenine/tryptophan ratio and NFκB activity in macrophages. Inhibition of the kynurenine-binding aryl hydrocarbon receptor by Epacadostat reduces kynurenine-induced tissue factor expression in activated macrophages, suggesting that enhanced IDO1 expression contributes to atherosclerosis progression through increased oxidative stress and inflammation.¹⁵¹

However, some kynurenine metabolites exhibit anti-atherosclerotic effects. For example, kynurenic acid enhances peroxisome proliferator-activated receptor delta (PPARδ) expression, reduces NFκB phosphorylation and decreases pro-inflammatory cytokine release in LPS-treated HUVEC and macrophages. Kynurenic acid also mitigates LPS-induced inflammation and apoptosis while promoting haem oxygenase-1 (HO-1) expression, which suppresses inflammation in HUVEC.¹⁵² Thus, the balance between pro-atherogenic and anti-atherogenic tryptophan metabolites may play a pivotal role in the development and progression of atherosclerosis.

There is a bidirectional relationship between atherosclerosis and CKD. Kidney dysfunction exacerbates atherosclerosis through the accumulation of uraemic toxins, increased oxidative stress, and vascular damage, while atherosclerotic plaque rupture contributes to kidney ischaemia and further renal injury. These interactions highlight the importance of managing both conditions together to reduce cardiovascular risk and prevent further organ damage. Early intervention and monitoring of kidney function in patients with atherosclerosis are essential for improving patient outcomes.

Kidney stones

KS are a common multifactorial urological condition characterised by the formation, retention, deposition and occasional passage of crystal aggregates in the urinary tract. Factors such as diet, sex, age and race influence the type of stones formed and their recurrence rate, with obesity and metabolic syndrome being major risk factors for KS development. Globally, calcium oxalate is recognised as the dominant component of KS.^153
–155 KS is currently recognised as a risk factor for CKD,¹⁵⁶ diabetes,¹⁵⁷ CVD,¹⁵⁸ and bone fractures.¹⁵⁹ Below, we review recent findings on the relationship between KS and atherosclerosis.

The role of atherosclerosis in KS development

The vascular theory of Randall plaque formation posits a connection between atherosclerosis-like processes and calcium oxalate KS development, suggesting that the repair of injured papillary vasculature leads to calcification near vessel walls, which subsequently transform into KS. Renal physiological properties, including turbulent blood flow at the papillary tip, higher osmolality between the renal cortex and papilla, and a decreasing oxygen-carrying capacity gradient, may facilitate atherosclerotic-like inflammatory responses with perivascular calcification, contributing to Randall plaque formation and KS progression.¹⁶⁰ A long-term observational study in young individuals in the United States found an association between urinary stone formation and subclinical carotid atherosclerosis, suggesting shared pathophysiological mechanisms.¹⁶¹

Elevated serum triglyceride (TG) levels have been specifically linked to an increased risk of urinary stones, whereas no significant associations were observed with other circulating lipids (e.g. LDL-C, HDL-C, APOA, APOB) or lipid-lowering treatments (HMGCR and PCSK9 inhibitors).¹⁶² However, another study found strong associations between carotid intima-media thickness (IMT), carotid scores, elevated serum TC and LDL levels and the presence of both calcium oxalate (CaOx) and calcium phosphate (CaP) stones, connecting dyslipidaemia, carotid atherosclerosis and KS.¹⁶³

A high-fat diet is a well-established risk factor for KS. Animal studies have demonstrated that such diets contribute to acidic urinary pH, promote the formation of uric acid and calcium-containing crystals and lead to renal injury and crystal retention in the urothelium (Figure 5).¹⁶⁴ Similarly, experiments on rats with metabolic syndrome showed that hyperoxaluria exacerbates renal CaOx crystal retention, causes severe morphological changes and significantly impairs renal function compared to control rats without metabolic syndrome.^165,166

Figure 5.

Mechanism of kidney stone formation. Unbalance diet (such as oxalate-rich diet) or genetic factors caused hyperoxaluria, hypercalciuria, hypocitraturia, hyperuricosuria or hyperuricosuria. Subsequently, these factors lead to the supersaturation of salts such as CaOx or uric acid or CaP, their nucleation, growth, aggregation and retention in the arterial wall, which resulted in kidney stone formation. Surplus ROS is formed by high uric acid or high oxalate, caused renal injury and promoted crystal nucleation and aggregation, thus facilitating kidney stones formation.

Oxidised LDL (oxLDL), a major driver of atherosclerosis, has been proposed as a causative link between atherosclerosis and KS. Although most oxLDL is taken up by the liver, approximately 2% is absorbed by the kidneys.¹⁶⁷ Under pathological conditions, renal uptake of oxLDL may increase. IL-1β has been shown to up-regulate the expression of the lectin-like oxLDL receptor 1 (LOX-1) in glomerular mesangial cells, promoting oxLDL uptake and accumulation, which can lead to lipid nephrotoxicity and podocyte damage.^168,169 OxLDL also enhances ADAM10 and CXCL16 expression, stimulating podocyte migration.¹⁷⁰ Interestingly, while no difference in circulating oxLDL levels was observed between patients with and without KS, KS patients exhibited higher urine oxLDL levels, which correlated with serum CRP levels and stone size. Additionally, increased renal oxLDL uptake was observed in KS patients, but not in controls without KS.¹⁷¹

The application of statins, commonly used for cholesterol lowering, has also shown benefits in KS management, further highlighting the close link between atherosclerosis and KS. Statins stabilise lipid parameters and provide protection against KS.¹⁷² In hyperlipidaemic and hyperoxaluric rat models, atorvastatin reduced renal CaOx stone deposition by decreasing free radical production and increasing osteopontin (OPN) expression, a key anti-lithic protein. Interestingly, this reduction in renal calcium deposition was accompanied by increased urinary bladder calcium crystals, suggesting a shift in the dominant crystal composition from CaOx to calcium phosphate.¹⁷³

In another rat model, atorvastatin increased superoxide dismutase (SOD) activity, mitigated kidney damage, reduced ER stress, apoptosis, and autophagy and decreased crystal deposition. Conversely, inhibiting SOD with diethyldithiocarbamic acid (DETC) aggravated crystal deposition and renal pathology, indicating the central role of SOD in atorvastatin’s protective effects.¹⁷⁴ Other studies confirmed that atorvastatin alleviates CaOx crystal-induced renal damage by suppressing oxidative stress and inflammation. Mechanistically, atorvastatin increased SOD levels, reduced malondialdehyde (MDA), lactate dehydrogenase (LDH) and ROS levels and inhibited the activation of TLR4/NFκB and NLRP3 inflammasome pathways, thereby decreasing pro-inflammatory cytokine secretion (IL-1β, IL-6, IL-18 and TNFα).¹⁷⁵ These findings suggest that atorvastatin’s antioxidant and anti-inflammatory properties may offer a novel therapeutic approach for KS prevention and treatment.

KS leads to atherosclerosis

A growing body of evidence demonstrates a strong association between KS and an elevated risk of ASCVD. Meta-analyses of cohort studies have shown that patients with KS are at increased risk of CHD and stroke.^176
–178 Stratified analyses across racial and ethnic groups revealed that non-Hispanic Black individuals with KS were 2.24 times more likely to experience an ASCVD event within the next decade compared to controls without KS.¹⁷⁹ Similarly, the Taiwan patients with KS had higher risk of MI, stroke and total cardiovascular events in the future.^180,181 In these populations, patients with CaOx and CaP KS were found to exhibit elevated serum TC and LDL levels, coupled with lower urinary citrate and increased carotid IMT, linking KS, dyslipidaemia and atherosclerosis.¹⁶³ Korean studies have further highlighted the association of KS with heightened risks of stroke and ischaemic heart disease.¹⁸² Key pathogenic factors linking KS and ASCVD include endothelial dysfunction, hyperuricaemia and systemic inflammation.^183
–185

Experimental studies using mouse models of CaOx KS have identified significant upregulation of genes involved in atherosclerosis, bone metabolism and calcium homeostasis. A range of atherosclerosis-related genes showed marked upregulation (more than tenfold), including adhesion molecules (CD44, VCAM-1), extracellular matrix components (matrix metallopeptidase 3, plasminogen activator inhibitor-1, collagen type III alpha 1 chain, fibrinogen beta chain, leukaemia inhibitory factor and macrophage scavenger receptor 1) and inflammatory mediators (chemokine ligand 2, C-C chemokine receptor type 1, chemokine ligand 1, secreted phosphoprotein 1 and IL-6).¹⁸⁶ These findings provide molecular insights into the mechanisms linking renal CaOx deposition with atherosclerosis.

The association between atherosclerosis and KS disease is driven by common mechanisms such as inflammation, dyslipidaemia and perivascular calcification. Atherosclerosis-like responses in kidney tissue promote stone formation, while KSs aggravate vascular inflammation and increase the risk of ASCVD. The up-regulation of atherosclerosis-promoting genes in KS disease further underscores the need for a holistic approach to treating both conditions. Effective management of lipid metabolism and inflammation could help reduce the risk of both cardiovascular and KS disease.

Thyroid dysfunction

Subclinical thyroid dysfunction, encompassing subclinical hypothyroidism (SHypo) and subclinical hyperthyroidism (SHyper), is characterised by abnormal serum thyroid-stimulating hormone (TSH) levels, while levels of free thyroid hormones (thyroxine [T4] and triiodothyronine [T3]) remain within the normal range. SHypo is defined by elevated TSH levels, while SHyper is marked by TSH levels below normal. SHypo is more prevalent (3%–10%) compared to SHyper (0.7%–10%).¹⁸⁷ This section explores the associations between SHypo/SHyper and increased ASCVD risk, biomarkers and underlying molecular mechanisms.

SHypo/SHyper and ASCVD risk

SHypo can be classified as mild or severe based on TSH levels, with most cases associated with antithyroid peroxidase antibodies, characteristic of Hashimoto’s thyroiditis.¹⁸⁸ SHypo is more common in iodine-sufficient regions, where excessive iodine intake may exacerbate its incidence.¹⁸⁹ Increasing evidence suggests that SHypo contributes to ASCVD risk through dyslipidaemia, diastolic left ventricular dysfunction, hypertension, insulin resistance and direct cardiovascular effects mediated by elevated TSH.^190,191

For example, a prospective cohort study in Korean adults with high CVD risk found that SHypo was associated with increased all-cause mortality and CVD events, particularly in individuals aged < 65 years.¹⁹² This finding aligns with meta-analyses showing that SHypo is linked to higher CVD event rates and all-cause mortality, though the association was less pronounced in low-risk populations.¹⁹³ Another meta-analysis, however, observed a connection between SHypo and CHD mortality but not other cardiovascular endpoints, such as heart failure or atrial fibrillation, with stronger associations in participants aged < 65 years.¹⁹⁴ Additionally, decreased central sensitivity to thyroid hormone in SHypo has been linked to hyperuricaemia and increased CVD risk.¹⁹⁵

Studies in children with SHypo have also highlighted early markers of atherosclerosis, including increased epicardial fat thickness (EFT) and CRP levels, along with reduced brachial artery flow-mediated dilation (FMD).^196,197 While adult patients with SHypo did not show significant differences in EFT, they exhibited increased carotid IMT and reduced aortic velocity propagation compared to controls.¹⁹⁸

Even within normal thyroid hormone ranges, higher TSH levels have been associated with adverse cardiometabolic profiles, including elevated glucose, haemoglobin A1c and TGs.¹⁹⁹ Dyslipidaemia (elevated LDL, TC, TG and reduced HDL), insulin resistance, CRP and homocysteine levels further link SHypo to ASCVD risk.^200
–204 Conversely, some studies have failed to demonstrate a significant correlation between SHypo or rising TSH and the 10-year risk of adverse cardiac events.²⁰⁵ These discrepancies may reflect the need for more nuanced analyses that account for ethnicity, genetics, age and comorbidities.

SHyper, defined by low serum TSH levels, is more prevalent in iodine-deficient regions and categorised into Grade 1 (low but detectable TSH) and Grade 2 (undetectable TSH).²⁰⁶ Like SHypo, SHyper has been linked to ASCVD and arrhythmias.^207
–209

Meta-analyses of prospective studies show that SHyper is associated with increased risks of CHD, CHD mortality and total mortality.^194,210 SHyper has also been linked to a higher risk of atrial fibrillation,²¹¹ In patients with acute coronary syndrome (ACS), low triiodothyronine syndrome (low T3) was associated with increased all-cause and cardiac mortality, whereas SHypo or SHyper showed no significant effect.²¹²

In conclusion, further studies are warranted to clarify the interplay between thyroid dysfunction, genetic predispositions, lifestyle factors and ASCVD risk and to identify effective screening and treatment strategies.

Mechanisms underlying thyroid dysfunction and increased ASCVD risk

Dyslipidaemia, hypertension, endothelial dysfunction and a hypercoagulable state have been proposed as the major risk factors linking thyroid dysfunction to ASCVD.²¹³ This connection may be explained through several functional properties of thyroid hormones (Figure 6). First, thyroid hormones promote the expression of hepatic LDL receptor, which regulates cholesterol transport and lipid metabolism by mediating the hepatic uptake of LDL from plasma.²¹⁴ Second, thyroid hormones play a crucial role in regulating BP and heart rate.^215,216 Third, thyroid hormones affect other risk factors, such as hypercoagulability and hyperhomocysteinaemia, which can facilitate atherosclerosis development in patients with thyroid dysfunction.²¹⁷ Recent studies have explored the contribution of thyroid dysfunction to atherosclerosis development.

Figure 6.

The summary of the pathogenic mechanisms connecting the increased risk of atherosclerosis development in hypothyroidism. Thyroid hormones regulate food intake, metabolism of lipids and glucose, thus affecting energy homeostasis and body weight. Increased adiposity caused hyperleptinaemia, which stimulated TSH secretion, which, in turn, promoted a differentiation of pre-adipocytes into adipocytes, thus closing the vicious cycle. Obesity is often accompanied by insulin resistance, which can stimulate leptin release and lead to hyperleptinaemia. The increased production of inflammatory cytokines in obesity reduced iodide uptake and may induce thyroid gland malfunction. Additionally, the described processes negatively affected blood vessels, causing endothelial dysfunction and arterial stiffness, and thus facilitating development of atherosclerosis and other cardiovascular diseases. The direct effects of thyroid hormones on heart rate, blood pressure, homocysteine levels and coagulation system are another processes increasing risk of ASCVD.

The reduction in brachial artery FMD is known as the primary sign of endothelial dysfunction and atherosclerotic changes. Thus, SHypo patients had lower FMD compared to euthyroid controls. However, treatment with levothyroxine, a synthetic form of the thyroid hormone thyroxine, which has been the primary treatment for SHypo since 1927,²¹⁸ normalised FMD in SHypo patients.^219,220

Adhesion molecules have also been associated with hyperthyroidism. SHyper patients exhibited higher VCAM-1 levels and a lower ankle-brachial index (ABI) – a simple test for peripheral artery disease – compared to euthyroid subjects. However, treatment with antithyroid drugs (thioamides, which block the biosynthesis of thyroid hormones) decreased free T4 levels, increased ABI and reduced VCAM-1 levels.²²¹ In a similar study, treatment of SHyper patients with thioamides (propylthiouracil and methimazole) normalised thyroid hormone levels to euthyroid conditions and was accompanied by a reduction in adhesion molecule levels (ICAM-1, VCAM-1 and E-selectin).²²²

Moreover, the molecular mechanism underlying the association between thyroid hormones and inflammation was elucidated in experiments on TSH receptor (Tshr)-deficient ApoE^−/− mice fed a Western diet. The ablation of the TSH receptor in ApoE^−/− mice reduced plaque area, macrophage burden in the plaques and the expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and CCL2) in the aorta, alongside a decrease in serum levels of IL-6 and TNFα, thus suppressing vascular inflammation and atherosclerosis progression. Further in vitro experiments on macrophages treated with TSH revealed a direct up-regulatory effect on inflammation marker expression (e.g. NOS2, IL-6, CX3CL1 and TNF-α) while down-regulating markers associated with inflammation resolution (e.g. ARG1, PPARγ, LXRA and ABCA1). TSH treatment also activated MAPKs (ERK1/2, p38α and JNK) and the IκB/p65 pathways in macrophages, promoting the production of pro-inflammatory cytokines and monocyte recruitment.²²³ Further research has shown that TSH activated Toll-like receptor 4 (TLR4),²²⁴ which is known to play a role in activating innate and adaptive immunity, inflammation, anti-tumour activity and other processes.^225,226 Subsequent application of specific inhibitors and siRNA demonstrated that the downstream pro-inflammatory signalling of the TSH receptor is mediated through G proteins: G13 (for ERK/p38) and G15 (for phospholipase C (PLC)/protein kinase C (PKC)/IκB pathways).²²⁷ In total, these findings highlight the detailed molecular mechanisms by which TSH aggravates vascular inflammation and promotes atherosclerosis, providing new insights into the treatment and prevention of atherosclerosis through monitoring thyroid hormone levels as an independent risk factor.

Thyroid dysfunction, including both hypothyroidism and hyperthyroidism, is closely linked to increased ASCVD risk. Thyroid hormones influence lipid metabolism, endothelial function and coagulation, all of which play crucial roles in the development of atherosclerosis. Mechanisms involving TSH receptor activation, MAPK pathways and inflammation contribute to vascular dysfunction and atherosclerotic progression. Understanding these molecular mechanisms offers new insights into managing thyroid dysfunction as an independent risk factor for ASCVD and atherosclerosis.

Conclusion

Atherosclerosis has long been known to be associated with the development of various multiorgan pathologies characterised by chronic inflammation, oxidative stress and dyslipidaemia. However, the significant advances made over the past decade have greatly expanded our understanding of how atherosclerosis-associated pathological changes affect the metabolism of vascular cells in different tissues and organs. In this review, we focused on the association between atherosclerosis and stroke, Alzheimer’s disease, NAFPD, CKD, KS disease and thyroid dysfunction. It is challenging to distinguish the specific pathways affected by atherosclerosis, as many of the adverse effects associated with atherosclerosis are also attributed to the manifestation of other closely related conditions (such as metabolic syndrome, diabetes mellitus, obesity and others) that share common risk factors with atherosclerosis (primarily hypertension, dyslipidaemia, smoking, advanced age, stress, genetic factors and many others).

A strong association has been established between atherosclerosis and IS, with napkin-ring sign plaques, a ‘spotty’ pattern of plaque calcification, and elevated serum levels of aldosterone, CRP, and ELAVL1 protein being potent stroke biomarkers. Interestingly, atherosclerosis and Alzheimer’s disease have been shown to promote each other through several pathways. Notably, the well-studied C/EBPβ/AEP signalling pathway has been demonstrated to connect atherosclerosis and AD through ApoE-mediated vascular dysfunction. Additionally, the ε4 allele of the ApoE gene has been associated with more severe forms of atherosclerosis and a higher rate of cognitive decline in AD.

Furthermore, CKD and atherosclerosis have been shown to exacerbate one another. Kidney dysfunction increases the accumulation of certain uraemic toxins, which impair the antioxidant system, increase ROS generation and promote oxidative damage, thereby exacerbating vascular dysfunction and the development of atherosclerosis. On the other hand, the rupture of atherosclerotic plaques can release CC into the bloodstream, which can become lodged in arterioles, leading to ischaemia and infarction in various tissues and organs, including the kidneys. Similarly, atherosclerosis and KSs have been linked through dyslipidaemia and oxLDL accumulation. Atherosclerosis-like responses to inflammation and perivascular calcification have been shown to promote KS formation. KSs, in turn, up-regulate a wide range of atherosclerosis-promoting genes (such as adhesion molecules, extracellular matrix molecules and pro-inflammatory cytokines), which increase the risk of ASCVD.

The role of atherosclerosis in pancreas dysfunction has been mechanistically explained by atherosclerosis-mediated reductions in blood flow to the pancreas, which causes islet hypoxia and β-cell dysfunction, leading to NAFPD and possibly accompanied by NAFLD and diabetes. Finally, dyslipidaemia, hypertension, endothelial dysfunction and a hypercoagulable state have been proposed as the major risk factors linking thyroid dysfunction and ASCVD. In vivo and in vitro experiments have demonstrated that thyroid hormones directly activate the expression and production of pro-inflammatory cytokines and adhesion molecules. In particular, TSH has been shown to aggravate vascular inflammation and promote atherosclerosis development by activating MAPKs, IκB/p65, TLR4 and PLC/PKC signalling pathways, at least partially through G proteins (G13 and G15).

The results discussed suggest that regular monitoring and timely treatment of atherosclerosis-related vascular risk factors may be a valuable strategy for treating and preventing Alzheimer’s disease, pancreas and thyroid dysfunctions, KSs and CKD. On the other hand, the pathologies of many organs may manifest through ASCVD, complicating diagnosis and treatment and potentially leading to life-threatening conditions. Overall, further studies deciphering the diverse mechanisms by which atherosclerosis is associated with multiple organ pathologies would help generate new therapeutic strategies to mitigate the adverse effects of atherogenesis on other organs.

Footnotes

Acknowledgements

Not applicable.

Author contributions

S.A.D and A.N.O. conceptualised the manuscript; S.A.D. writing – original draft preparation; A.V.C., N.V.E., A.L.R., A.E.K., V.N.S. and A.N.O. review and editing; A.L.R. and N.V.E. validation; A.V.C. and A.E.K. formal analysis; V.N.S and A.N.O. obtained funding and supervised. All authors have read and agreed to the published version of the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by Russian Science Foundation, Grant# 24-15-00123 (conceptualisation; writing – original draft preparation, writing – review and editing; formal analysis; validation; funding acquisition; project administration).

Ethical considerations

Not applicable.

Informed consent

Not applicable.

Trial registration

Not applicable.

ORCID iDs

Siarhei A Dabravolski

Alexander N Orekhov

References

Libby

The changing landscape of atherosclerosis. Nature 2021; 592: 524–533.

Fan

Watanabe

Atherosclerosis: known and unknown. Pathol Int 2022; 72: 151–160.

Zhao

Wang

Zhao

TY.

The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis. Atherosclerosis 2020; 303: 36–42.

Mezentsev

Bezsonov

Kashirskikh

, et al. Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines 2021; 9: 600.

Poznyak

Sukhorukov

Surkova

, et al. Glycation of LDL: AGEs, impact on lipoprotein function, and involvement in atherosclerosis. Front Cardiovasc Med 2023; 10: 1094188.

Roy

Orecchioni

Ley

How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol 2022; 22: 251–265.

Leszczynska

O’Doherty

Farrell

, et al. Differentiation of vascular stem cells contributes to ectopic calcification of atherosclerotic plaque. Stem Cells 2016; 34: 913–923.

Hutcheson

Goettsch

Bertazzo

, et al. Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques. Nature Mater 2016; 15: 335–343.

Russo

Fracassi

Kurihara

, et al. Healed plaques in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 2020; 40: 1587–1597.

10.

Gutierrez

Turan

Hoh

, et al. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurol 2022; 21: 355–368.

11.

Gonzalez

Dungan

Smart

, et al. Inflammation resolution in the cardiovascular system: arterial hypertension, atherosclerosis, and ischemic heart disease. Antioxid Redox Signal 2024; 40: 292–316.

12.

Porsch

Mallat

Binder

CJ.

Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc Res 2021; 117(13): 2544–2562.

13.

Dabravolski

Bezsonov

Baig

, et al. Mitochondrial lipid homeostasis at the crossroads of liver and heart diseases. Int J Mol Sci 2021; 22: 6949.

14.

Zhao

Kong

Cui

, et al. Communication between nonalcoholic fatty liver disease and atherosclerosis: focusing on exosomes. Eur J Pharmac Sci 2024; 193: 106690.

15.

Zhu

, et al. Two sides of the same coin: non-alcoholic fatty liver disease and atherosclerosis. Vasc Pharmacol 2024; 154: 107249.

16.

Wolf

Ley

Immunity and inflammation in atherosclerosis. Circ Res 2019; 124: 315–327.

17.

Ilatovskaya

Halade

DeLeon-Pennell

KY.

Adaptive immunity-driven inflammation and cardiovascular disease. Am J Physiol Heart Circ Physiol 2019; 317: H1254–H1257.

18.

Fernández-Gallego

Castillo-González

Méndez-Barbero

, et al. The impact of type 2 immunity and allergic diseases in atherosclerosis. Allergy 2022; 77: 3249–3266.

19.

Keeter

Stahr

, et al. Atherosclerosis and multi-organ-associated pathologies. Semin Immunopathol 2022; 44: 363–374.

20.

Poller

Nahrendorf

Swirski

FK.

Hematopoiesis and cardiovascular disease. Circ Res 2020; 126: 1061–1085.

21.

Dragoljevic

Westerterp

Veiga

, et al. Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis. Clin Sci 2018; 132: 1889–1899.

22.

Csányi

Singla

Arterial lymphatics in atherosclerosis: old questions, new insights, and remaining challenges. J Clin Med 2019; 8: 495.

23.

, et al. Lymphatic system identification, pathophysiology and therapy in the cardiovascular diseases. J Mol Cell Cardiol 2019; 133: 99–111.

24.

Zheng

Ren

Peng

, et al. Lymphatic vessels: a potential approach to the treatment of atherosclerosis? Lymphat Res Biol 2018; 16: 498–506.

25.

Antoniades

Tousoulis

Vavlukis

, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J 2023; 44: 3827–3844.

26.

Mazitova

Márquez-Sánchez

Koltsova

EK.

Fat and inflammation: adipocyte-myeloid cell crosstalk in atherosclerosis. Front Immunol 2023; 14: 1238664.

27.

Chen

McVey

Shen

, et al. Phenotypic switching of vascular smooth muscle cells in atherosclerosis. J Cell Physiol 2023; 12: e031121.

28.

Allahverdian

Chaabane

Boukais

, et al. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res 2018; 114: 540–550.

29.

Ramel

Gayral

Sarthou

M-K

, et al. Immune and smooth muscle cells interactions in atherosclerosis: how to target a breaking bad dialogue? Front Pharmacol 2019; 10: 1276.

30.

Harrington

Dey

Yunus

, et al. Psoriasis as a human model of disease to study inflammatory atherogenesis. Am J Physiol Heart Circ Physiol 2017; 312: H867–H873.

31.

Piaserico

Orlando

Messina

Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci 2022; 23: 9063.

32.

Sajja

Joshi

Teague

, et al. Potential immunological links between psoriasis and cardiovascular disease. Front Immunol 2018; 9: 1234.

33.

Kurilenko

Fatkhullina

Mazitova

, et al. Act locally, act globally – microbiota, barriers, and cytokines in atherosclerosis. Cells 2021; 10: 348.

34.

Weissman

Sinh

Mehta

, et al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: the role of chronic inflammation. World J Gastrointest Pathophysiol 2020; 11: 104–113.

35.

Zhao

Zhu

, et al. Diabetes mellitus to accelerated atherosclerosis: shared cellular and molecular mechanisms in glucose and lipid metabolism. J Cardiovasc Trans Res 2024; 17: 133–152.

36.

Wang

, et al. Diabetes mellitus promotes the development of atherosclerosis: the role of NLRP3. Front Immunol 2022; 13: 900254.

37.

Saini

Guada

Yavagal

DR.

Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology 2021; 97: S6–S16.

38.

Cole

JW.

Large artery atherosclerotic occlusive disease. Continuum (Minneap Minn) 2017; 23: 133–157.

39.

Wei

San

, et al. Retrospective analysis of prognosis and risk factors of patients with stroke by TOAST. Medicine 2018; 97: e0412.

40.

Kim

Nah

H-W

Park

, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke 2012; 43: 3313–3318.

41.

Parish

Arnold

Clarke

, et al. Assessment of the role of carotid atherosclerosis in the association between major cardiovascular risk factors and ischemic stroke subtypes. JAMA Netw Open 2019; 2: e194873.

42.

Rosário

Fonseca

AC.

Update on biomarkers associated with large-artery atherosclerosis stroke. Biomolecules 2023; 13: 1251.

43.

Zhao

Meng

, et al. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke 2016; 47: 2025–2030.

44.

Chen

H-Y

Xiao

Z-Z

Ling

, et al. ELAVL1 is transcriptionally activated by FOXC1 and promotes ferroptosis in myocardial ischemia/reperfusion injury by regulating autophagy. Mol Med 2021; 27: 14.

45.

Song

Chen

Pan

, et al. Unraveling the role of collateral circulation and serum ELAVL1 in carotid atherosclerosis and ischemic stroke: insights from clinical observations. Adv Clin Exp Med 2023; 33: 921–928.

46.

Zhou

Zhao

, et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017; 38: 33–40.

47.

Mahmoud

Mentias

Elgendy

, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1,152,407 subjects. BMJ Open 2018; 8: e020498.

48.

Zhang

Liu

Shi

Association between migraine and risk of stroke: a systematic review and meta-analysis. Neurol Sci 2022; 43: 4875–4889.

49.

van Os

HJA

Mulder

Broersen

, et al. Migraine and cerebrovascular atherosclerosis in patients with ischemic stroke. Stroke 2017; 48: 1973–1975.

50.

Williams

Newby

Nicol

ED.

Coronary atherosclerosis imaging by CT to improve clinical outcomes. J Cardiovasc Comp Tomogr 2019; 13: 281–287.

51.

Potter

Vagal

Goyal

, et al. CT for treatment selection in acute ischemic stroke: a code stroke primer. Radiographics 2019; 39: 1717–1738.

52.

Zou

Meng

, et al. Increased incidence of napkin-ring sign plaques on cervicocerebral computed tomography angiography associated with the risk of acute ischemic stroke occurrence. Eur Radiol 2023; 34(7): 4438–4447.

53.

Wang

Chen

, et al. Arterial calcification and its association with stroke: implication of risk, prognosis, treatment response, and prevention. Front Cell Neurosci 2022; 16: 845215.

54.

De Araújo

ALV

Santos

Bittencourt

, et al. Ischemic stroke caused by large-artery atherosclerosis: a red flag for subclinical coronary artery disease. Front Neurol 2023; 14: 1082275.

55.

Tábuas-Pereira

Sargento-Freitas

Silva

, et al. Intracranial internal carotid artery wall calcification in ischemic strokes treated with thrombolysis. Eur Neurol 2018; 79: 21–26.

56.

Shimoyama

Gaj

Nakamura

, et al. Quantitative CTA vascular calcification, atherosclerosis burden, and stroke mechanism in patients with ischemic stroke. J Neurol Sci 2023; 449: 120667.

57.

Tamaru

Fujii

Fukunaga

, et al. Impact of spotty calcification on long-term prediction of future revascularization: a prospective three-vessel intravascular ultrasound study. Heart Vessels 2016; 31: 881–889.

58.

Zhang

Yang

Gan

, et al. Spotty calcium on cervicocerebral computed tomography angiography associates with increased risk of ischemic stroke. Stroke 2019; 50: 859–866.

59.

Zhang

Wang

Chen

, et al. Serum aldosterone is associated with cerebral artery atherosclerosis and calcification. J Stroke Cerebrovasc Dis 2019; 28: 523–530.

60.

Nehme

Zibara

Cellular distribution and interaction between extended renin-angiotensin-aldosterone system pathways in atheroma. Atherosclerosis 2017; 263: 334–342.

61.

Sun

J-H

Tan

J-T.

Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med 2014; 2: 80.

62.

Wang

Liu

, et al. Effects of blood pressure in the early phase of ischemic stroke and stroke subtype on poststroke cognitive impairment. Stroke 2018; 49: 1610–1617.

63.

Dempsey

Varghese

Jackson

, et al. Carotid atherosclerotic plaque instability and cognition determined by ultrasound-measured plaque strain in asymptomatic patients with significant stenosis. J Neurosurg 2018; 128: 111–119.

64.

Wang

Ding

, et al. Carotid atherosclerotic calcification characteristics relate to post-stroke cognitive impairment. Front Aging Neurosci 2021; 13: 682908.

65.

Khan

Barve

Kumar

MS.

Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Curr Neuropharmacol 2020; 18: 1106–1125.

66.

Saeed

Lopez

Cohen

, et al. Cardiovascular disease and Alzheimer’s disease: the heart–brain axis. J Am Heart Assoc 2023; 12: e030780.

67.

Puig

Combs

CK.

Expression and function of APP and its metabolites outside the central nervous system. Exp Gerontol 2013; 48: 608–611.

68.

Guo

Wang

Chen

, et al. Functions of amyloid precursor protein in metabolic diseases. Metabolism 2021; 115: 154454.

69.

Krämer

Brettschneider

Lennerz

, et al. Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. Sci Rep 2018; 8: 16594.

70.

Stamatelopoulos

Sibbing

Rallidis

, et al. Amyloid-beta (1–40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol 2015; 65: 904–916.

71.

Tibolla

Norata

Meda

, et al. Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis 2010; 210: 78–87.

72.

Van De Parre

TJL

Guns

P-JDF

Fransen

, et al. Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. Atherosclerosis 2011; 216: 54–58.

73.

Ellis

Fang

Maheshwari

, et al. Lipid oxidation and modification of amyloid-β (Aβ) in vitro and in vivo. J Alzheimers Dis 2010; 22: 593–607.

74.

Gong

Xing

Zheng

, et al. Increased expression of chitinase 3-like 1 in aorta of patients with atherosclerosis and suppression of atherosclerosis in apolipoprotein E-knockout mice by chitinase 3-like 1 gene silencing. Mediators Inflamm 2014; 2014: 1–12.

75.

Hwang

Cho

Lee

, et al. Aberrant expressions of pathogenic phenotype in Alzheimer’s diseased transgenic mice carrying NSE-controlled APPsw. Exp Neurol 2004; 186: 20–32.

76.

Ridker

Chasman

Rose

, et al. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J Am Heart Assoc 2014; 3: e000897.

77.

Jafari

Elias

Mohsenin

Increased plasma YKL-40/chitinase-3-like-protein-1 is associated with endothelial dysfunction in obstructive sleep apnea. PLoS ONE 2014; 9: e98629.

78.

Jung

Kim

Park

, et al. Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice. Theranostics 2018; 8: 749–766.

79.

Visconte

Canino

Guidetti

, et al. Amyloid precursor protein is required for in vitro platelet adhesion to amyloid peptides and potentiation of thrombus formation. Cell Signal 2018; 52: 95–102.

80.

Canobbio

Catricalà

Di Pasqua

, et al. Immobilized amyloid Aβ peptides support platelet adhesion and activation. FEBS Lett 2013; 587: 2606–2611.

81.

Kucheryavykh

Dávila-Rodríguez

Rivera-Aponte

, et al. Platelets are responsible for the accumulation of β-amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis. Brain Res Bullet 2017; 128: 98–105.

82.

Xiang

Carotid atherosclerosis promotes the progression of Alzheimer’s disease: a three-year prospective study. Exp Therap Med 2017; 14: 1321–1326.

83.

Yaffe

Vittinghoff

Pletcher

, et al. Early adult to midlife cardiovascular risk factors and cognitive function. Circulation 2014; 129: 1560–1567.

84.

Faraco

Iadecola

Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810–817.

85.

Faraco

Park

Zhou

, et al. Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab 2016; 36: 241–252.

86.

Eglit

GML

Weigand

Nation

, et al. Hypertension and Alzheimer’s disease: indirect effects through circle of Willis atherosclerosis. Brain Commun 2020; 2: fcaa114.

87.

Wang

Huang

, et al. High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 × Tg) mouse model of Alzheimer’s disease associated with chronic platelet activation. Alz Res Therapy 2021; 13: 144.

88.

Rahman

Baquero

Choudhury

, et al. C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis. Atherosclerosis 2016; 250: 172–179.

89.

Wang

Liu

Chen

, et al. Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer’s disease. Proc Natl Acad Sci USA 2018; 115: E12427–E12434.

90.

Lei

Kang

Ahn

, et al. C/EBPβ/AEP signalling regulates the oxidative stress in malignant cancers, stimulating the metastasis. Mol Cancer Therap 2021; 20: 1640–1652.

91.

Yang

Chen

C/EBPβ is a key transcription factor of ox-LDL inducing THP-1 cells to release multiple pro-inflammatory cytokines. Inflamm Res 2021; 70: 1191–1199.

92.

Zhang

Song

Liu

, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med 2014; 20: 1254–1262.

93.

Ozawa

Sato

Mori

, et al. Legumain promotes atherosclerotic vascular remodelling. Int J Mol Sci 2019; 20: 2195.

94.

Wang

Z-H

Gong

Liu

, et al. C/EBPβ regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer’s disease. Nat Commun 2018; 9: 1784.

95.

Zahid

Rogowski

Ponce

, et al. CCAAT/enhancer-binding protein beta (C/EBPβ) knockdown reduces inflammation, ER stress, and apoptosis, and promotes autophagy in oxLDL-treated RAW264.7 macrophage cells. Mol Cell Biochem 2020; 463: 211–223.

96.

Zhang

Song

Liu

, et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat Commun 2015; 6: 8762.

97.

Zhang

Obianyo

Dall

, et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease. Nat Commun 2017; 8: 14740.

98.

Sun

Lin

Chen

, et al. Legumain suppresses OxLDL-induced macrophage apoptosis through enhancement of the autophagy pathway. Gene 2018; 652: 16–24.

99.

Liao

Chen

Liu

, et al. C/EBPβ/AEP signalling couples atherosclerosis to the pathogenesis of Alzheimer’s disease. Mol Psychiatry 2022; 27: 3034–3046.

100.

Raulin

A-C

Doss

Trottier

, et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegen 2022; 17: 72.

101.

Falsetti

Viticchi

Buratti

, et al. Interactions between atrial fibrillation, cardiovascular risk factors, and ApoE genotype in promoting cognitive decline in patients with Alzheimer’s disease: a prospective cohort study. J Alzheimers Dis 2018; 62: 713–725.

102.

Wang

Chen

Wang

, et al. Endogenous protective factors and potential therapeutic agents for diabetes-associated atherosclerosis. Front Endocrinol 2022; 13: 821028.

103.

Ishii

Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: what are the medical treatments to prevent cardiovascular events in such patients?

J Diabetes Invest 2022; 13: 1114–1121.

104.

Caiati

Stanca

Lepera

ME.

Free radicals and obesity-related chronic inflammation contrasted by antioxidants: a new perspective in coronary artery disease. Metabolites 2023; 13: 712.

105.

Haidar

Horwich

Obesity, cardiorespiratory fitness, and cardiovascular disease. Curr Cardiol Rep 2023; 25(11): 1565–1571.

106.

Ogilvie

RF.

The islands of langerhans in 19 cases of obesity. J Pathol 1933; 37: 473–481.

107.

Van Geenen

E-JM

Smits

Schreuder

TCMA

, et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010; 39: 1185–1190.

108.

Sotoudehmanesh

Tahmasbi

Sadeghi

, et al. The prevalence of nonalcoholic fatty pancreas by endoscopic ultrasonography. Pancreas 2019; 48: 1220–1224.

109.

Tariq

Nayudu

Akella

, et al. Non-alcoholic fatty pancreatic disease: a review of literature. Gastroenterol Res 2016; 9: 87–91.

110.

Begovatz

Koliaki

Weber

, et al. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia 2015; 58: 1646–1655.

111.

Ozturk

Dogan

Celikkanat

, et al. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2018; 30: 411–417.

112.

Kul

Karadeniz

Dursun

, et al. Non-alcoholic fatty pancreas disease is associated with increased epicardial adipose tissue and aortic intima-media thickness. Acta Cardiologica Sinica 2019; 35(2): 118–125.

113.

Koo

Denenberg

Wright

, et al. The association between pancreatic fat and systemic calcified atherosclerosis. Pancreas 2020; 49: e16–e18.

114.

Kim

Chun

Park

, et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. Diabetes Res Clin Pract 2014; 106: 590–596.

115.

Sun

Fan

Wang

, et al. Computed tomography-estimated pancreatic steatosis is associated with carotid plaque in type 2 diabetes mellitus patients: a cross-sectional study from China. Diabetes Metab Syndr Obes 2021; 14: 1329–1337.

116.

Alexandre-Heymann

Barral

Dohan

, et al. Patients with type 2 diabetes present with multiple anomalies of the pancreatic arterial tree on abdominal computed tomography: comparison between patients with type 2 diabetes and a matched control group. Cardiovasc Diabetol 2020; 19: 122.

117.

Inker

Grams

Levey

, et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium. Am J Kidney Dis 2019; 73: 206–217.

118.

Suriyong

Ruengorn

Shayakul

, et al. Prevalence of chronic kidney disease stages 3–5 in low- and middle-income countries in Asia: a systematic review and meta-analysis. PLoS ONE 2022; 17: e0264393.

119.

Webster

Nagler

Morton

, et al. Chronic kidney disease. Lancet 2017; 389: 1238–1252.

120.

Mozaffari

Ajabshir

Alizadeh

Dietary approaches to stop hypertension and risk of chronic kidney disease: a systematic review and meta-analysis of observational studies. Clin Nutr 2020; 39: 2035–2044.

121.

Shen

Cai

Sun

, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine 2017; 55: 66–76.

122.

Bayliss

Zhuang

Cholesterol crystal embolism and chronic kidney disease. Int J Mol Sci 2017; 18: 1120.

123.

Borg

Kriegbaum

Grand

, et al. Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death. BMC Prim Care 2023; 24: 128.

124.

Fokoua-Maxime

Seukep

Bellouche

, et al. Prevalence of unrecognized or ‘silent’ myocardial ischemia in chronic kidney disease patients: protocol for a systematic review and meta-analysis. PLoS ONE 2021; 16: e0256934.

125.

Chen

Mohler

Xie

, et al. Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31: 1145–1151.

126.

Major

Cheng

MRI

Grant

, et al. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 2018; 13: e0192895.

127.

Yamada

Tsuruya

Kitazono

, et al. Emerging cross-talks between chronic kidney disease–mineral and bone disorder (CKD–MBD) and malnutrition–inflammation complex syndrome (MICS) in patients receiving dialysis. Clin Exp Nephrol 2022; 26: 613–629.

128.

Maas

Donners

MMPC

Van Der Vorst

EPC

. ADAM10 and ADAM17, major regulators of chronic kidney disease induced atherosclerosis? Int J Mol Sci 2023; 24: 7309.

129.

Scolari

Ravani

Atheroembolic renal disease. Lancet 2010; 375: 1650–1660.

130.

Firas

Deepthi

Jagadeesh

, et al. Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. J Biomed Res 2017; 31: 82.

131.

Baumer

McCurdy

Boisvert

WA.

Formation and cellular impact of cholesterol crystals in health and disease. Adv Biol 2021; 5: 2100638.

132.

Agrawal

Ziccardi

Witzke

, et al. Cholesterol embolization syndrome: an under-recognized entity in cardiovascular interventions. J Interven Cardiol 2018; 31: 407–415.

133.

Van Rosendael

Kamperidis

Van Der Kley

, et al. Atherosclerosis burden of the aortic valve and aorta and risk of acute kidney injury after transcatheter aortic valve implantation. J Cardiovasc Comp Tomogr 2015; 9: 129–138.

134.

Ozkok

Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag 2019; 15: 209–220.

135.

Niyonzima

Bakke

Gregersen

, et al. Cholesterol crystals use complement to increase NLRP3 signalling pathways in coronary and carotid atherosclerosis. EBioMedicine 2020; 60: 102985.

136.

Niyonzima

Samstad

Aune

, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal–induced inflammatory responses by reducing complement activation. J Immunol 2015; 195: 257–264.

137.

Allawi

AAD

. Malnutrition, inflammation and atherosclerosis (MIA syndrome) in patients with end stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr Clin Res Rev 2018; 12: 91–97.

138.

Bural

Torigian

Sözmen

, et al. Comparison of atherosclerotic inflammation and calcification in subjects with end stage renal disease (ESRD) on hemodialysis to normal controls utilizing 18F-FDG PET/CT. Hell J Nucl Med 2018; 21: 169–174.

139.

Kopel

Kaufman

Hamburg

, et al. Endothelium-dependent and -independent vascular function in advanced chronic kidney disease. Clin J Am Soc Nephrol 2017; 12: 1588–1594.

140.

Van Der Vorm

Visser

Huskens

, et al. Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease. Clin Kidney J 2020; 13: 72–74.

141.

Kwiatkowska

Hermanowicz

Mysliwiec

, et al. Oxidative storm induced by tryptophan metabolites: missing link between atherosclerosis and chronic kidney disease. Oxid Med Cell Long 2020; 2020: 1–16.

142.

Lee

W-C

L-C

Chen

J-B

, et al. Indoxyl sulfate-induced oxidative stress, mitochondrial dysfunction, and impaired biogenesis are partly protected by vitamin C and N-acetylcysteine. ScientificWorldJournal 2015; 2015: 620826.

143.

Zhou

, et al. Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro. Vasc Pharmacol 2020; 131: 106763.

144.

Shen

W-C

Liang

C-J

Huang

T-M

, et al. Indoxyl sulfate enhances IL-1β-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFκB/AP-1 pathway. Arch Toxicol 2016; 90: 2779–2792.

145.

Kuo

K-L

Zhao

J-F

Huang

P-H

, et al. Indoxyl sulfate impairs valsartan-induced neovascularization. Redox Biol 2020; 30: 101433.

146.

Zheng

, et al. Grape seed proanthocyanidin extract protects human umbilical vein endothelial cells from indoxyl sulfate-induced injury via ameliorating mitochondrial dysfunction. Renal Failure 2016; 38: 100–108.

147.

Six

Gross

Rémond

, et al. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120. Atherosclerosis 2015; 243: 248–256.

148.

Zou

M-H.

Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation. Front Biosci 2015; 20: 1116–1143.

149.

Kaminski

Pawlak

Karbowska

, et al. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease. Int Urol Nephrol 2018; 50: 127–135.

150.

Theiler-Schwetz

Trummer

Grübler

, et al. Associations of parameters of the tryptophan–kynurenine pathway with cardiovascular risk factors in hypertensive patients. Nutrients 2023; 15: 256.

151.

Watanabe

Koyama

Yamashita

, et al. Indoleamine 2,3-dioxygenase 1 in coronary atherosclerotic plaque enhances tissue factor expression in activated macrophages. Res Pract Thromb Haemost 2018; 2: 726–735.

152.

Lee

Park

Jeong

, et al. Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARδ/HO-1-dependent pathway. Mol Cell Endocrinol 2019; 495: 110510.

153.

Siener

Nutrition and kidney stone disease. Nutrients 2021; 13: 1917.

154.

Ferraro

Bargagli

Trinchieri

, et al. Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian–vegan diets. Nutrients 2020; 12: 779.

155.

Stamatelou

Goldfarb

DS.

Epidemiology of kidney stones. Healthcare 2023; 11: 424.

156.

Uribarri

Chronic kidney disease and kidney stones. Curr Opin Nephrol Hypertens 2020; 29: 237–242.

157.

Aune

Mahamat-Saleh

Norat

, et al. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2018; 33: 1033–1047.

158.

Arafa

Eshak

Iso

Oxalates, urinary stones and risk of cardiovascular diseases. Med Hypotheses 2020; 137: 109570.

159.

Prochaska

Bisphosphonates and management of kidney stones and bone disease. Curr Opin Nephrol Hypertens 2021; 30: 184–189.

160.

Bagga

Chi

Miller

, et al. New insights into the pathogenesis of renal calculi. Urol Clin N Am 2013; 40: 1–12.

161.

Reiner

Kahn

Eisner

, et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 2011; 185: 920–925.

162.

Tan

Hong

Sun

, et al. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study. Front Endocrinol 2023; 14: 1301163.

163.

Huang

Liao

Liu

CJ.

Calcium kidney stones are associated with increased risk of carotid atherosclerosis: the link between urinary stone risks, carotid intima-media thickness, and oxidative stress markers. J Clin Med 2020; 9: 729.

164.

Schmiedl

Schwille

Bonucci

, et al. Nephrocalcinosis and hyperlipidemia in rats fed a cholesterol- and fat-rich diet: association with hyperoxaluria, altered kidney and bone minerals, and renal tissue phospholipid-calcium interaction. Urol Res 2000; 28: 404–415.

165.

Okamoto

Kohjimoto

Iba

, et al. Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys. Int J of Urol 2010; 17: 996–1003.

166.

Sáenz-Medina

Jorge

Corbacho

, et al. Metabolic syndrome contributes to renal injury mediated by hyperoxaluria in a murine model of nephrolithiasis. Urolithiasis 2018; 46: 179–186.

167.

Nakano

Kawashima

Miyake

, et al. 123I–Labeled oxLDL is widely distributed throughout the whole body in mice. Nucl Med Mol Imaging 2018; 52: 144–153.

168.

Wang

Sun

Zhou

, et al. OxLDL-induced lipid accumulation in glomerular podocytes: role of IFN-γ, CXCL16, and ADAM10. Cell Biochem Biophys 2014; 70: 529–538.

169.

Liu

Lin

, et al. Interleukin-1β promotes Ox-LDL uptake by human glomerular mesangial cells via LOX-1. Int J Med Sci 2020; 17: 1056–1061.

170.

Chen

Wang

, et al. OxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4. Mol Med Rep 2020; 22: 1976–1984.

171.

Liu

C-J

K-T

Tsai

Y-S

, et al. Increased renal uptake and urine excretion of oxidized LDL is possibly associated with formation of large calcium oxalate nephrolithiasis: a preliminary study. World J Urol 2023; 41: 1423–1430.

172.

Cohen

Adamsky

Nottingham

, et al. Impact of statin intake on kidney stone formation. Urology 2019; 124: 57–61.

173.

Liu

Tsai

Huang

HS.

Atorvastatin decreases renal calcium oxalate stone deposits by enhancing renal osteopontin expression in hyperoxaluric stone-forming rats fed a high-fat diet. Int J Mol Sci 2022; 23: 3048.

174.

Kang

Sun

Deng

, et al. Autophagy-endoplasmic reticulum stress inhibition mechanism of superoxide dismutase in the formation of calcium oxalate kidney stones. Biomed Pharmacother 2020; 121: 109649.

175.

Sun

Liu

Guan

, et al. Atorvastatin inhibits renal inflammatory response induced by calcium oxalate crystals via inhibiting the activation of TLR4/NF-κB and NLRP3 inflammasome. IUBMB Life 2020; 72: 1065–1074.

176.

Liu

Zeng

, et al. Kidney stones and cardiovascular risk: a meta-analysis of cohort studies. Am J Kidney Dis 2014; 64: 402–410.

177.

Peng

J-P

Zheng

Kidney stones may increase the risk of coronary heart disease and stroke: a PRISMA-compliant meta-analysis. Medicine 2017; 96: e7898.

178.

Yuan

Zhou

H-Y

, et al. Association between kidney stones and risk of developing stroke: a meta-analysis. Neurol Sci 2021; 42: 4521–4529.

179.

Glover

Bass

Carithers

, et al. Association of kidney stones with atherosclerotic cardiovascular disease among adults in the United States: considerations by race-ethnicity. Physiol Behav 2016; 157: 63–66.

180.

Hsu

C-Y

Chen

Y-T

Huang

P-H

, et al. The association between urinary calculi and increased risk of future cardiovascular events: a nationwide population-based study. J Cardiol 2016; 67: 463–470.

181.

Chen

H-Y

Chang

C-J

Yang

Y-C

, et al. Renal stones and gallstones correlated with the ten-year risk estimation of atherosclerotic cardiovascular disease based on the pooled cohort risk assessment of males aged 40–79. J Mol Sci 2023; 12: 2309.

182.

Kim

Bang

Min

, et al. Association of nephrolithiasis with the risk of cardiovascular diseases: a longitudinal follow-up study using a national health screening cohort. BMJ Open 2020; 10: e040034.

183.

Saenz-Medina

Muñoz

Rodriguez

, et al. Endothelial dysfunction: an intermediate clinical feature between urolithiasis and cardiovascular diseases. Int J Mol Sci 2022; 23: 912.

184.

Nishizawa

Maeda

Shimomura

Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res 2022; 45: 635–640.

185.

Liu

C-J

Jan

H-C

Huang

H-S.

Risks of carotid artery stenosis and atherosclerotic cardiovascular disease in patients with calcium kidney stone. Assessment of systemic inflammatory biomarkers. J Pers Med 2022; 12: 1697.

186.

Kusumi

Barr-Beare

Saxena

, et al. Renal calcium oxalate deposits induce a pro-atherosclerotic and pro-osteoporotic response in mice. J Cell Biochem 2017; 118: 2744–2751.

187.

Wang

Sun

Yang

, et al. The management and metabolic characterization: hyperthyroidism and hypothyroidism. Neuropeptides 2023; 97: 102308.

188.

Cooper

Biondi

Subclinical thyroid disease. Lancet 2012; 379: 1142–1154.

189.

Meng

Liu

, et al. Association between iodine status and prevalence of hypothyroidism, autoimmune thyroiditis, and thyroid nodule: a cross-sectional study in Shandong Province, China. Biol Trace Elem Res. Epub ahead of print 15 April 2024. DOI: 10.1007/s12011-024-04179-4.

190.

Gluvic

Zafirovic

Obradovic

, et al. Hypothyroidism and risk of cardiovascular disease. Curr Pharmac Design 2022; 28: 2065–2072.

191.

Papadopoulou

A-M

Bakogiannis

Skrapari

, et al. Thyroid dysfunction and atherosclerosis: a systematic review. In Vivo 2020; 34: 3127–3136.

192.

Moon

Kong

Choi

, et al. Relation of subclinical hypothyroidism is associated with cardiovascular events and all-cause mortality in adults with high cardiovascular risk. Am J Cardiol 2018; 122: 571–577.

193.

Moon

Kim

, et al. Subclinical hypothyroidism and the risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Thyroid 2018; 28: 1101–1110.

194.

Sun

Yao

Fang

, et al. Relationship between subclinical thyroid dysfunction and the risk of cardiovascular outcomes: a systematic review and meta-analysis of prospective cohort studies. Int J Endocrinol 2017; 2017: 1–15.

195.

Sun

Teng

Zhao

, et al. Impaired sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subjects with subclinical hypothyroidism. Thyroid 2022; 32: 376–384.

196.

Farghaly

Metwalley

Raafat

, et al. Epicardial fat thickness in children with subclinical hypothyroidism and its relationship to subclinical atherosclerosis: a pilot study. Horm Res Paediatr 2019; 92: 99–105.

197.

Sahu

Mishra

Baliarsinha

, et al. Utility of epicardial fat thickness in subclinical hypothyroid children to determine existence of subclinical atherosclerosis in them. Indian J Endocr Metab 2022; 26: 483.

198.

Asoğlu

Akbulut

Doğan

, et al. Evaluation of the aortic velocity propagation, epicardial fat thickness, and carotid intima-media thickness in patients with subclinical hypothyroidism. Rev Cardiovasc Med 2021; 22: 959.

199.

Shim

YS.

Association of thyroid-stimulating hormone and thyroid hormones with cardiometabolic risk factors in euthyroid children and adolescents aged 10–18 years: a population-based study. Sci Rep 2019; 9: 15476.

200.

Ebrahimpour

Vaghari-Tabari

Qujeq

, et al. Direct correlation between serum homocysteine level and insulin resistance index in patients with subclinical hypothyroidism: does subclinical hypothyroidism increase the risk of diabetes and cardio vascular disease together? Diabetes Metab Syndr 2018; 12: 863–867.

201.

Dey

Kanneganti

Das

A study of the cardiac risk factors emerging out of subclinical hypothyroidism. J Family Med Prim Care 2019; 8: 2439.

202.

Goyal

Singla

, et al. Subclinical hypothyroidism and associated cardiovascular risk factor in perimenopausal females. J Midlife Health 2020; 11: 6.

203.

Shankar

Narasimhappa

Subclinical Hypothyroidism (SH) and Atherogenic Index of Plasma (AIP) in Women: A Case-Control Study From a Tertiary Care Hospital in South India. Cureus 2020; 12(9): e10636.

204.

Janovsky

CCPS

Bittencourt

Goulart

, et al. Unfavorable triglyceride-rich particle profile in subclinical thyroid disease: a cross-sectional analysis of ELSA-Brasil. Endocrinology 2021; 162: bqaa205.

205.

Nair

Kumar

Raveendran

, et al. Subclinical hypothyroidism and cardiac risk: lessons from a South Indian population study. Indian J Endocr Metab 2018; 22: 217.

206.

Donangelo

Suh

SY.

Subclinical hyperthyroidism: when to consider treatment. Am Fam Physician 2017; 95: 710–716.

207.

Manolis

Melita

, et al. Subclinical thyroid dysfunction and cardiovascular consequences: an alarming wake-up call? Trends Cardiovasc Med 2020; 30: 57–69.

208.

Vidili

Delitala

Manetti

Subclinical hyperthyroidism: the cardiovascular point of view. Eur Rev Med Pharmacol Sci 2021; 25: 3264–3271.

209.

Delitala

Subclinical hyperthyroidism and the cardiovascular disease. Horm Metab Res 2017; 49: 723–731.

210.

Sohn

Lee

, et al. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis and systematic review of cohort studies. Endocrinol Metab 2020; 35: 786–800.

211.

Floriani

Gencer

Collet

T-H

, et al. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J 2018; 39: 503–507.

212.

Cao

Jiao

, et al. Association between mild thyroid dysfunction and clinical outcome in acute coronary syndrome undergoing percutaneous coronary intervention. Cardiol J 2020; 27: 262–271.

213.

Cappola

Desai

Medici

, et al. Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment. Circulation 2019; 139: 2892–2909.

214.

Ritter

Amano

Hollenberg

AN.

Thyroid hormone signaling and the liver. Hepatology 2020; 72: 742–752.

215.

Davis

Goglia

Leonard

JL.

Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 2016; 12: 111–121.

216.

Casis

Echeazarra

Sáenz-Díez

, et al. Deciphering the roles of triiodothyronine (T3) and thyroid-stimulating hormone (TSH) on cardiac electrical remodelling in clinical and experimental hypothyroidism. J Physiol Biochem 2024; 80: 1–9.

217.

Razvi

Jabbar

Pingitore

, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol 2018; 71: 1781–1796.

218.

Kahaly

Gottwald-Hostalek

Use of levothyroxine in the management of hypothyroidism: a historical perspective. Front Endocrinol 2022; 13: 1054983.

219.

Niknam

Khalili

Khosravi

, et al. Endothelial dysfunction in patients with subclinical hypothyroidism and the effects of treatment with levothyroxine. Adv Biomed Res 2016; 5: 38.

220.

Hosseini

Bakhtyari

Heshmat-Ghahdarijani

, et al. Evaluation of endothelial function in exogenous subclinical hyperthyroidism and the effect of treatment. Adv Biomed Res 2016; 5: 173.

221.

Y-H

Lee

I-T.

Hyperthyroidism and vascular cell adhesion molecule-1 are associated with a low ankle-brachial index. Sci Rep 2020; 10: 17076.

222.

Wisnu

Alwi

Nafrialdi

, et al. The differential effects of propylthiouracil and methimazole as Graves’ disease treatment on vascular atherosclerosis markers: a randomized clinical trial. Front Endocrinol 2021; 12: 796194.

223.

Yang

Chen

, et al. Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques. J Exp Med 2019; 216: 1182–1198.

224.

Bao

Duan

, et al. Thyroid-stimulating hormone may participate in insulin resistance by activating toll-like receptor 4 in liver tissues of subclinical hypothyroid rats. Mol Biol Rep 2023; 50: 10637–10650.

225.

Wei

Zhang

, et al. Toll-like receptor 4: a potential therapeutic target for multiple human diseases. Biomed Pharmacother 2023; 166: 115338.

226.

Kashani

Zandi

Pourbagheri-Sigaroodi

, et al. The role of toll-like receptor 4 (TLR4) in cancer progression: a possible therapeutic target? J Cell Physiol 2021; 236: 4121–4137.

227.

Yang

Zhang

, et al. TSH activates macrophage inflammation by G13- and G15-dependent pathways. Endocrinology 2021; 162: bqab077.

Association between atherosclerosis and the development of multi-organ pathologies

Abstract

Keywords

Introduction

Association between ASCVD and IS

Association between ASCVD and AD

The role of AD in atherosclerosis progression

The role of atherosclerosis in AD progression

Pancreas and ASCVD

Chronic kidney disease

The role of atherosclerosis in CKD

The role of CKD in atherosclerosis development

Kidney stones

The role of atherosclerosis in KS development

KS leads to atherosclerosis

Thyroid dysfunction

SHypo/SHyper and ASCVD risk

Mechanisms underlying thyroid dysfunction and increased ASCVD risk

Conclusion

Footnotes

Acknowledgements

Author contributions

Declaration of conflicting interests

Funding

Ethical considerations

Informed consent

Trial registration

ORCID iDs

References